All News

ACR Best

ACR21 Best Abstracts - Day 1

Jack Cush, MD

The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.

Read Article
acr_session2.jpeg

Opening Day Report

Jack Cush, MD

The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).

Read Article
RheumNow Podcast square

RheumNow Podcast – Quackademia (10.15.2021)

Jack Cush, MD

Dr. Jack Cush reviews the FDA approvals, news and the latest journal articles from the past week on RheumNow.com.

Read Article
aosd.CXR_.jpg (keep)

Still’s Disease Following COVID-19 Vaccination

Jack Cush, MD

Both systemic onset juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease are acquired autoinflammatory disorders of uncertain etiology. Yet recent reports of AOSD onset and flare following COVID-19 vaccinations may have important mechanistic implications.

Read Article
RheumNow Podcast square

RheumNow Podcast – #ACA: Ask Cush Anything (10.8.2021)

Jack Cush, MD

Arthritis numbers are rising, and people are finally talking about osteoarthritis. Also, ACR 2021 is just a few weeks away - are you ready? Finally, I'll review cases and questions submitted by viewers in Ask Cush Anything (#ACA). This, and nearly a dozen news items and reports, are discussed in this week's podcast. Let's begin.

Read Article
antisynthetase,myositis,nail,erythema

Clinical Associations with Myositis Antibodies

Jack Cush, MD

While myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) may have prognostic value through their clinical associations, many patients will not have them and overall, they are poorly predictive of a malignancy risk. 

Read Article
DAPSA PsA measure

Pathways to a Psoriatic Arthritis Diagnosis

Jack Cush, MD

Ogdie and colleagues have retrospectively analyzed a longitudinal cohort of psoriatic arthritis (PsA) patients, showing that only two-thirds of PsA are diagnosed by rheumatologists, PCPs and dermatologists, with significant differences in what preemptive symptoms were noted by different subspecialties.

Read Article
exhaustion,depression

Lupus Frailty Index Predicts Organ Damage

MedPage Today

Patients with longstanding systemic lupus erythematosus (SLE) who were considered frail were more likely to accrue disease damage over time, a secondary analysis of data from a Chicago lupus cohort found.

Read Article
RheumNow Podcast square

RheumNow Podcast – Jack of All Subspecialties (10.1.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article
Plenary at #ACR21 Renal outcome Risk of minority patients with pediatric #lupus @rheumnow abst#0956 inpatient hospitalizations. https://t.co/HK8w246Dsn
Bella Mehta bella_mehta ( View Tweet)
"We need to do more than improving quality of care to close the gap in racial disparities." - Dr. J Chang Trends of adverse renal outcomes⬇️w/time in children hosp w/SLE. Improvements seen across racial/ethnic group, but black-white disparity persists abst#0956 #ACR21 @rheumnow https://t.co/HcOwQiKCb2
TheDaoIndex KDAO2011 ( View Tweet)
TNFi + JIA = watch the skin! A nearly 3fold increase of paradoxal psoriasis in JIA patients exposed to TNFi reported in the CARRA registry w/ incidence rate the highest on children receiving adalimumab. #Abst0241 @RheumNow #ACR2021 https://t.co/uXOwV2RlGu https://t.co/8f8mvVUkV2

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
#ACR21 #Abstr0261 In stable Non sJIA, is it safe to taper or stop MTX? Of 375 pts in CARRA registry, 24% tapered and 14% stopped MTX. No diff in flare rates btw those continued vs tapered/stopped. Sustained remission was in ⬆️tapered vs stopped @RheumNow https://t.co/Mm1yfzRBQz https://t.co/rkHvXWj2oO

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Juvenile dermatomyositis, with Gottren's and diffuse hyperpigmentation Regional Winner of Europe & Central Asia Image Competition: Rheum Dz in Patients of Color #ACR21 @rheumnow https://t.co/vxayxgINa8
TheDaoIndex KDAO2011 ( View Tweet)
This 15-day-old boy developed this rash, which was diagnosed with neonatal lupus; anti-Ro and anti-La Abs were present, in both, mother and child. The mother never had had symptoms suggesting SLE or any autoimmune disease. The rash healed after 45 days; the boy is doing great😍 https://t.co/fYB0IzE7kY
Emilio Martin Mola emartinmola ( View Tweet)
Retrospective study hospitalized new-onset systemic JIA (2008-19):52 children’s hospitals & 534 sJiAshows 29% rx w/ biologics & 58% steroids. Over time Biologic use increased & MTX decreased. Biologic correlated w/ Hi hospital volume, ICU stay, later years https://t.co/blbOps9zVQ

Links:

Dr. John Cush RheumNow ( View Tweet)

Costs of #JIA are substantial, total costs up to 44,832 USD annually. Direct costs up to $32,446 USD, accounting for 55-98 % of total. $$$ mostly related to meds; cost go up 3 fold after biologic initiation. (JIA Indirect costs are underrepresented) https://t.co/rukJPWqD0y

Links:

Dr. John Cush RheumNow ( View Tweet)

Most common reasons for starting canakinumab? Survey of 58 MDs (caring for 147 febrile pts) 1) perceived efficacy(81%), 2) lack of prior response (41%), 3) good safety (40%). Efficacy w/ HIDS/MKD (91%), no response w/ FMF (52%) https://t.co/JjxaUyBnyB

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 52 pts with Juvenile Systemic Sclerosis (JSSc) -10% were without skin dz (SSc sine scleroderma). 7 pts reviewed, all had cardiac dz (86 vs 16%; 3 cardiomyopathy, 3PAH), longer Dx delay (20 vs 8 mos), worse outcomes, (42 v 6%) https://t.co/7wGuX8QVBO https://t.co/XdTK7AlPrs

Links:

Dr. John Cush RheumNow ( View Tweet)
Using EHR data from the UK, the frequency of children and young people with JIA in 2018 was studied. Age standardised incidence rate =5.61 per 100 000; prevalence rate=43.5 per 100 000. 5-yr incidence rates did not change over time. https://t.co/mwmf5nktkF

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×